Penpulimab: FDA-Approved Anti-PD-1 Antibody for Nasopharyngeal Carcinoma
Penpulimab is FDA-approved specifically for nasopharyngeal carcinoma (NPC) in two settings: first-line treatment of recurrent or metastatic non-keratinizing NPC in combination with chemotherapy, and as monotherapy for recurrent metastatic non-keratinizing NPC after prior treatment. 1
Approved Indications
Penpulimab has two distinct FDA-approved indications 1:
- First-line treatment: Recurrent or metastatic non-keratinizing nasopharyngeal carcinoma in combination with cisplatin/carboplatin plus gemcitabine
- Later-line treatment: Recurrent metastatic non-keratinizing nasopharyngeal carcinoma as monotherapy
Important limitation: Despite being studied in other malignancies including NSCLC, Hodgkin's lymphoma, and DLBCL, penpulimab currently has no FDA approval for these indications 2, 3, 4.
Dosing Regimens
Combination Therapy (First-Line)
200 mg IV every 3 weeks in combination with either cisplatin or carboplatin plus gemcitabine 1. This regimen demonstrated a median PFS of 9.6 months versus 7.0 months with chemotherapy alone (HR 0.45, P < 0.0001), with an ORR of 68.1% 5.
Monotherapy (Later-Line)
200 mg IV every 2 weeks as a single agent 1. In heavily pretreated metastatic NPC patients (≥2 prior lines), monotherapy achieved an ORR of 28.0% with median PFS of 3.6 months and median OS of 22.8 months 3.
Eligibility Criteria
Based on the FDA label and clinical trial data 1, 5, 3:
Patients should have:
- Confirmed non-keratinizing nasopharyngeal carcinoma histology
- Recurrent or metastatic disease not amenable to curative treatment
- Adequate performance status (trials used ECOG 0-1)
Key contraindications 1:
- Active autoimmune disease or documented history requiring systemic immunosuppression
- Current use of immunosuppressive agents
- Prior allogeneic hematopoietic stem cell transplantation (due to risk of graft-versus-host disease)
Common Adverse Effects
Treatment-Related Adverse Events
In combination therapy, grade ≥3 treatment-related AEs occurred in 89.0% of patients 5:
Most common hematologic toxicities:
- Neutropenia (56.2%)
- Leukopenia (54.1%)
- Anemia (45.2%)
Immune-Related Adverse Events (irAEs)
Penpulimab has a notably low incidence of severe irAEs compared to other anti-PD-1 antibodies, attributed to its Fc-engineered IgG1 backbone that eliminates FcγR binding and reduces ADCC, ADCP, and proinflammatory cytokine release 6.
Grade ≥3 irAEs: Only 4.1% in first-line combination therapy 5 and 7.6% in heavily pretreated monotherapy patients 3. Across 465 patients in multiple trials, only 3.2% experienced grade ≥3 irAEs with no deaths from irAEs reported 6.
Most common irAEs:
Rare but serious irAEs documented in case reports:
- Autoimmune hemolytic anemia (grade 4) requiring plasmapheresis 2
- Immune-related cholangitis and pancreatitis 8
Critical Safety Monitoring
Monitor regularly for:
- Complete blood counts (for cytopenias)
- Liver function tests (ALT, AST, bilirubin)
- Thyroid function tests
- Direct antiglobulin test (DAT) and hemolysis markers (LDH, haptoglobin) if anemia develops 2
Infusion-related reactions can occur; monitor during and after infusion 1.
Key Clinical Pearls
Penpulimab's unique Fc engineering distinguishes it from other anti-PD-1 antibodies by providing better stability than IgG4 backbone antibodies while maintaining efficacy with reduced immune-mediated toxicity 6. It demonstrates slower dissociation from PD-1 (slower off-rate) compared to nivolumab or pembrolizumab and binds to the PD-1 N-glycosylation site at N58 6.
For severe irAEs: Permanently discontinue for grade 4 events. For the rare occurrence of severe autoimmune hemolytic anemia, consider plasmapheresis as adjunctive therapy when corticosteroids alone provide insufficient rapid symptom control 2.
Embryo-fetal toxicity: Penpulimab can cause fetal harm; verify pregnancy status before treatment and advise effective contraception 1.